Nasdaq

Sun BioPharma, Inc. Summarizes SBP-101 Phase 1 Clinical Data Presented at ASCO 2020 Annual Gastrointestinal Cancers Symposium

SBP-101 was well tolerated in combination with gemcitabine and nab-paclitaxel Objective Response Rate (ORR) was 62% by RECIST criteria Study expansion in patients with pancreatic cancer planned to ...
Yahoo Finance

Panbela Therapeutics, Inc. Completes Enrollment in its Phase 1b Trial Investigating SBP-101 Combination Therapy for First Line Metastatic Pancreatic Cancer

MINNEAPOLIS, Dec. 08, 2020 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc. (Nasdaq: PBLA), a clinical stage biopharmaceutical company developing disruptive therapeutics for the treatment of patients ...
Yahoo Finance

Sun BioPharma, Inc. Receives FDA Fast Track Designation for SBP-101

MINNEAPOLIS, June 30, 2020 (GLOBE NEWSWIRE) -- Sun BioPharma, Inc. (SNBP), a clinical stage biopharmaceutical company developing disruptive therapeutics for the treatment of patients with pancreatic ...
Business Insider

Sun Biopharma, Inc. Announces Initiation of First-Line Combination Study of Sbp-101 With Gemcitabine and Nab-Paclitaxel in Patients With Pancreatic Cancer• First-In-Human ...

MINNEAPOLIS, Jan. 29, 2018 (GLOBE NEWSWIRE) -- – Sun BioPharma, Inc. (OTCQB:SNBP), a clinical stage biopharmaceutical company developing disruptive therapeutics for the treatment of pancreatic ...
Business Insider

Sun Biopharma, Inc. Files United States Patent Protecting the Manufacturing Process for Its Lead Drug Candidate, SBP-101

MINNEAPOLIS, MN, Feb. 27, 2018 (GLOBE NEWSWIRE) -- Sun BioPharma, Inc. (OTCQB:SNBP), a clinical stage biopharmaceutical company developing disruptive therapeutics for the treatment of pancreatic ...